ClinicalTrials.gg
CompletedNCT00768755Updated Oct 28, 2015Results posted

Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer

A Phase 1/2 interventional study of axitinib and axitinib in Carcinoma, Non-Small Cell Lung, sponsored by Pfizer. Completed at 52 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-28.

Sponsored by Pfizer · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer — 15 open to participants now, 26 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · Pfizer.

Enrollment
38th of 136
180 · median 79
Started
2009
with 1 other
Phase 1/2
13 of 158
1 open now
Registered
37th of 158
by date

Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 38th largest by enrollment of the 136 interventional ones that give a count, is one of 2 that started in 2009, is one of 13 in phase 1/2, and was the 37th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

15 of the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, or all of them as a file.
02

Study summary

AG-013736 (axitinib) in combination with cisplatin and pemetrexed will be evaluated as first-line treatment of patients with locally advanced, recurrent, or metastatic non-squamous, non small cell lung cancer (NSCLC).

03

Conditions studied

  • Carcinoma, Non-Small Cell Lung

Keywords

  • non-squamous NSCLC
  • axitinib
  • pemetrexed/cisplatin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of adeno-, large cell or bronchioalveolar non-small cell lung cancer
  • Cytologic specimens for diagnosis or for cell type classification must have been obtained from bronchial brushings or washings or from needle aspiration of a defined lesion. Sputum cytology alone will not be acceptable for diagnosis or for cell type classification.
  • Patients with mixed NSCLC with predominantly squamous cell carcinoma should be classified as squamous and thus do not qualify for this study.
  • Stage IIIB with malignant effusion (with cytologic confirmation of malignant pleural or pericardial effusion), Stage IV, or recurrent disease after definitive loco-regional therapy.
  • Candidate for primary treatment with cisplatin and pemetrexed

Exclusion criteria

Exclusion Criteria:

  • Any histological/cytological evidence of predominantly squamous NSCLC.
  • Small cell or carcinoid lung cancer patients are also ineligible.
  • NSCLC that cannot be classified as one of the eligible histologies (adenocarcinoma, large cell or bronchioalveolar).
  • Prior systemic therapy for Stage IIIB (with malignant effusion), Stage IV, or recurrent NSCLC. (Prior treatment with systemic therapy as chemotherapy or in conjunction with radiotherapy for Stage II or III NSCLC is permitted if the last dose of chemotherapy was completed 12 months or more prior to randomization).
  • Prior treatment with a VEGF or VEGFR inhibitor.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    I

    Axitinib (continuous) + Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance

    Drug: axitinib

  • Experimental
    II

    Axitinib (modified) + Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance

    Drug: axitinib

  • Active comparator
    III

    pemetrexed and cisplatin

    Drug: chemotherapy

  • Experimental
    IV

    Axitinib interrupted before each chemo cycle (Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance

    Drug: axitinib

  • Active comparator
    V

    pemetrexed and cisplatin

    Drug: chemotherapy

Interventions

  • 5mg BID po up to max 10mg BID po

    Also known as: AG-013736

  • 5mg BID po up to max 10mg BID po paused for 3 days before each cycle of concomitant chemotherapy

    Also known as: AG-013736

  • Drugchemotherapy

    Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles

    Also known as: alimta

  • 5mg BID po up to max 10mg BID po paused before each concomitant chemotherapy

  • Drugchemotherapy

    Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles

    Also known as: alimta

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Time in months from the date of randomization to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus minus the date of randomization plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]); death was determined from AE data (where the outcome was "Death") or from the end of study data.

    Time frame: Phase 2 baseline until the date of first documented progression or death due to any cause or initiation of subsequent anticancer therapy, assessed every 6 weeks up to 84 weeks

Secondary outcomes

  1. Overall Survival (OS)

    Time in months from the date of randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4. Death was determined from AE data (where outcome was death) or from follow-up contact data (where the participant current status was death).

    Time frame: Baseline until death or collected bimonthly following discontinuation of study treatment until at least 1 year after randomization of the last participant

  2. Percentage of Participants With Objective Response (OR)

    Percentage of participants with OR based assessment of confirmed complete response (CR)/confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors(RECIST).Confirmed responses: those persist on repeat imaging study at least 4 weeks after initial documentation of response.CR: disappearance of all lesions (target/non target) and no appearance of new lesions.PR: those with at least 30 % decrease in sum of longest dimensions of target lesions taking as reference baseline sum longest dimensions,without progression of non target lesions and no appearance of new lesions.

    Time frame: Phase 2 baseline until the date of first documented progression or discontinuation from the study due to any cause or initiation of subsequent anticancer therapy, assessed every 6 weeks up to 84 weeks

  3. Duration of Response (DR)

    Time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause, whichever occurs first. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

    Time frame: Phase 2 baseline until the date of first documented progression or discontinuation from the study due to any cause or initiation of subsequent anticancer therapy, assessed every 6 weeks up to 84 weeks

  4. Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Inventory (MDASI) Symptom Severity Score

    Symptom severity score is comprised of average of 13 MDASI core items (pain, fatigue, nausea, disturbed sleep, distressed, shortness of breath, remembering things, lack of appetite, drowsy, dry mouth, sadness, vomiting, numbness or tingling) and ranges from 0 to 10. Participants were asked to rate severity of each symptom at their worst in last 24 hours; each item rated from 0 to 10, with 0 = symptom not present and 10 = as bad as you can imagine. Lower scores indicated better outcome.

    Time frame: Phase 2 baseline (Cycle1/Day1), Cycle1/Day8, then Day 1 and 8 of each cycle of chemotherapy (C) up to CycleC6, Day 1 of each cycle of single-agent phase (A) up to CycleA8 and end of treatment (EOT)

  5. Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Inventory (MDASI) Symptom Interference Score

    Symptom interference score is comprised of average of 6 function items from MDASI core (general activity, mood, work, relations with others, walking, and enjoyment of life) and ranges from 0 to 10. Participants were asked to rate how much symptoms have interfered in last 24 hours; each item rated from 0 to 10, with 0 = did not interfere and 10 = interfered completely. Lower scores indicated better outcome.

    Time frame: Phase 2 baseline (Cycle1/Day1), Cycle1/Day8, then Day 1 and 8 of each cycle of chemotherapy (C) up to CycleC6, Day 1 of each cycle of single-agent phase (A) up to CycleA8 and EOT

07

Results

Posted Mar 30, 2012

Participant flow

Phase 1
Participant flow — Phase 1
MilestoneAxitinib + Pemetrexed/Cisplatin (Phase 1)Axitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2)Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2)Pemetrexed/Cisplatin (Phase 2)
Started10000
Completed0000
Not completed10000
Withdrew: Death6000
Withdrew: Other4000
Phase 2
Participant flow — Phase 2
MilestoneAxitinib + Pemetrexed/Cisplatin (Phase 1)Axitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2)Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2)Pemetrexed/Cisplatin (Phase 2)
Started0555857
Treated0555855
Completed0000
Not completed0555857
Withdrew: Death0374831
Withdrew: Protocol violation0201
Withdrew: Lost to follow-up0114
Withdrew: Withdrawal by subject0101
Withdrew: Other0124
Withdrew: Study terminated by sponsor013714
Withdrew: Randomized but not treated0002

Outcome measures

PrimaryProgression-Free Survival (PFS)

Time in months from the date of randomization to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus minus the date of randomization plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]); death was determined from AE data (where the outcome was "Death") or from the end of study data.

Time frame:
Phase 2 baseline until the date of first documented progression or death due to any cause or initiation of subsequent anticancer therapy, assessed every 6 weeks up to 84 weeks
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsAxitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2)Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2)Pemetrexed/Cisplatin (Phase 2)
Progression-Free Survival (PFS)8.0 (6.7 to 10.0)8.1 (6.8 to 9.9)7.1 (5.8 to 9.4)
Statistical analysis
  • Axitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2) vs Pemetrexed/Cisplatin (Phase 2) · Log Rank · p = 0.3037 · Hazard ratio (hr): 0.831 · 95% CI 0.508 to 1.360One-sided log-rank test at alpha = 0.20 significance level was used.
  • Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2) vs Pemetrexed/Cisplatin (Phase 2) · Log Rank · p = 0.3565 · Hazard ratio (hr): 0.947 · 95% CI 0.580 to 1.546One-sided log-rank test at alpha = 0.20 significance level was used.
SecondaryOverall Survival (OS)

Time in months from the date of randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4. Death was determined from AE data (where outcome was death) or from follow-up contact data (where the participant current status was death).

Time frame:
Baseline until death or collected bimonthly following discontinuation of study treatment until at least 1 year after randomization of the last participant
Reported as:
Median · months
Overall Survival (OS)
monthsAxitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2)Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2)Pemetrexed/Cisplatin (Phase 2)
Overall Survival (OS)17.0 (12.6 to 22.5)14.7 (11.5 to 18.1)15.9 (11.1 to NA)
Statistical analysis
  • Axitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2) vs Pemetrexed/Cisplatin (Phase 2) · Log Rank · p = 0.5785 · Hazard ratio (hr): 1.046 · 95% CI 0.648 to 1.690One-sided log-rank test at alpha = 0.20 significance level was used.
  • Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2) vs Pemetrexed/Cisplatin (Phase 2) · Log Rank · p = 0.9392 · Hazard ratio (hr): 1.449 · 95% CI 0.919 to 2.285One-sided log-rank test at alpha = 0.20 significance level was used.
SecondaryPercentage of Participants With Objective Response (OR)

Percentage of participants with OR based assessment of confirmed complete response (CR)/confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors(RECIST).Confirmed responses: those persist on repeat imaging study at least 4 weeks after initial documentation of response.CR: disappearance of all lesions (target/non target) and no appearance of new lesions.PR: those with at least 30 % decrease in sum of longest dimensions of target lesions taking as reference baseline sum longest dimensions,without progression of non target lesions and no appearance of new lesions.

Time frame:
Phase 2 baseline until the date of first documented progression or discontinuation from the study due to any cause or initiation of subsequent anticancer therapy, assessed every 6 weeks up to 84 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response (OR)
percentage of participantsAxitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2)Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2)Pemetrexed/Cisplatin (Phase 2)
Percentage of Participants With Objective Response (OR)45.5 (32.0 to 59.4)39.7 (27.0 to 53.4)26.3 (15.5 to 39.7)
Statistical analysis
  • Axitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2) vs Pemetrexed/Cisplatin (Phase 2) · Cochran-Mantel-Haenszel · p = 0.0143 · Risk ratio (rr): 1.753 · 95% CI 1.047 to 2.935
  • Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2) vs Pemetrexed/Cisplatin (Phase 2) · Cochran-Mantel-Haenszel · p = 0.0665 · Risk ratio (rr): 1.512 · 95% CI 0.870 to 2.626
SecondaryDuration of Response (DR)

Time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause, whichever occurs first. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

Time frame:
Phase 2 baseline until the date of first documented progression or discontinuation from the study due to any cause or initiation of subsequent anticancer therapy, assessed every 6 weeks up to 84 weeks
Reported as:
Median · months
Duration of Response (DR)
monthsAxitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2)Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2)Pemetrexed/Cisplatin (Phase 2)
Duration of Response (DR)7.82 (5.6 to 11.4)6.73 (5.0 to 7.8)7.10 (4.2 to 24.7)
SecondaryChange From Baseline in Monroe Dunaway (MD) Anderson Symptom Inventory (MDASI) Symptom Severity Score

Symptom severity score is comprised of average of 13 MDASI core items (pain, fatigue, nausea, disturbed sleep, distressed, shortness of breath, remembering things, lack of appetite, drowsy, dry mouth, sadness, vomiting, numbness or tingling) and ranges from 0 to 10. Participants were asked to rate severity of each symptom at their worst in last 24 hours; each item rated from 0 to 10, with 0 = symptom not present and 10 = as bad as you can imagine. Lower scores indicated better outcome.

Time frame:
Phase 2 baseline (Cycle1/Day1), Cycle1/Day8, then Day 1 and 8 of each cycle of chemotherapy (C) up to CycleC6, Day 1 of each cycle of single-agent phase (A) up to CycleA8 and end of treatment (EOT)
Reported as:
Mean · units on a scale
Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Inventory (MDASI) Symptom Severity Score
units on a scaleAxitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2)Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2)Pemetrexed/Cisplatin (Phase 2)
Phase 2 baseline (CycleC1/Day 1), (n= 55, 55, 53)1.75 (1.32 to 2.18)2.09 (1.67 to 2.50)1.80 (1.33 to 2.27)
Change at CycleC1/Day 8, (n= 49, 49, 50)1.55 (1.09 to 2.02)0.36 (0.00 to 0.72)0.95 (0.56 to 1.34)
Change at CycleC2/Day1 (n= 51, 51, 41)0.12 (-0.26 to 0.49)-0.05 (-0.46 to 0.35)0.39 (0.01 to 0.77)
Change at CycleC2/Day8 (n= 39, 38, 34)1.52 (0.98 to 2.06)0.39 (-0.14 to 0.92)0.69 (0.24 to 1.13)
Change at CycleC3/Day1 (n= 45, 47, 39)0.57 (0.16 to 0.97)0.29 (-0.13 to 0.71)0.32 (-0.15 to 0.79)
Change at CycleC3/Day8 (n= 38, 35, 32)1.33 (0.75 to 1.92)0.87 (0.18 to 1.56)1.15 (0.61 to 1.68)
Change at CycleC4/Day1 (n= 43, 43, 38)0.85 (0.28 to 1.42)0.48 (-0.06 to 1.02)0.37 (-0.05 to 0.79)
Change at CycleC4/Day8 (n= 33, 33, 27)1.37 (0.64 to 2.09)0.90 (0.30 to 1.51)1.48 (0.77 to 2.19)
Change at CycleC5/Day1 (n= 35, 34, 29)0.59 (0.05 to 1.12)0.48 (-0.17 to 1.12)0.72 (0.25 to 1.18)
Change at CycleC5/Day8 (n= 29, 26, 25)1.19 (0.38 to 2.00)0.82 (0.10 to 1.55)1.16 (0.46 to 1.87)
Change at CycleC6/Day1 (n= 27, 28, 28)0.67 (0.04 to 1.30)0.42 (-0.22 to 1.06)0.67 (0.11 to 1.23)
Change at CycleC6/Day8 (n= 25, 25, 21)1.44 (0.71 to 2.17)0.85 (0.23 to 1.47)1.28 (0.48 to 2.08)
Change at CycleA1/Day1 (n= 35, 33, 21)0.63 (0.27 to 0.99)0.24 (-0.32 to 0.79)0.68 (-0.09 to 1.45)
Change at CycleA2/Day1 (n= 32, 30, 14)0.36 (-0.11 to 0.83)-0.01 (-0.55 to 0.54)0.14 (-0.49 to 0.77)
Change at CycleA3/Day1 (n= 27, 26, 10)0.25 (-0.30 to 0.79)0.01 (-0.63 to 0.65)0.12 (-0.38 to 0.63)
Change at CycleA4/Day1 (n= 22, 25, 0)0.03 (-0.65 to 0.70)0.07 (-0.56 to 0.70)NA (NA to NA)
Change at CycleA5/Day1 (n= 17, 23, 12)0.19 (-0.78 to 1.16)-0.12 (-0.73 to 0.48)0.30 (-0.37 to 0.96)
Change at CycleA6/Day1 (n= 17, 16, 10)0.10 (-0.56 to 0.77)-0.23 (-1.21 to 0.76)0.14 (-0.83 to 1.11)
Change at CycleA7/Day1 (n= 15, 15, 0)-0.26 (-0.99 to 0.47)-0.33 (-1.37 to 0.70)NA (NA to NA)
Change at CycleA8/Day1 (n= 15, 14, 10)-0.28 (-0.91 to 0.35)0.30 (-0.76 to 1.36)0.02 (-1.15 to 1.20)
Change at CycleA9/Day1 (n= 13, 11, 0)-0.46 (-1.29 to 0.38)0.34 (-0.51 to 1.19)NA (NA to NA)
Change at CycleA10/Day1 (n= 0, 10, 0)NA (NA to NA)0.61 (-0.38 to 1.59)NA (NA to NA)
Change at EOT (n= 40, 35, 31)0.66 (0.12 to 1.20)1.02 (0.40 to 1.63)0.99 (0.33 to 1.64)
SecondaryChange From Baseline in Monroe Dunaway (MD) Anderson Symptom Inventory (MDASI) Symptom Interference Score

Symptom interference score is comprised of average of 6 function items from MDASI core (general activity, mood, work, relations with others, walking, and enjoyment of life) and ranges from 0 to 10. Participants were asked to rate how much symptoms have interfered in last 24 hours; each item rated from 0 to 10, with 0 = did not interfere and 10 = interfered completely. Lower scores indicated better outcome.

Time frame:
Phase 2 baseline (Cycle1/Day1), Cycle1/Day8, then Day 1 and 8 of each cycle of chemotherapy (C) up to CycleC6, Day 1 of each cycle of single-agent phase (A) up to CycleA8 and EOT
Reported as:
Mean · units on a scale
Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Inventory (MDASI) Symptom Interference Score
units on a scaleAxitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2)Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2)Pemetrexed/Cisplatin (Phase 2)
Phase 2 baseline (CycleC1/Day 1), (n= 55, 55, 53)2.36 (1.64 to 3.08)2.97 (2.27 to 3.68)2.64 (1.92 to 3.37)
Change at CycleC1/Day 8, (n= 49, 49, 50)1.48 (0.80 to 2.16)-0.03 (-0.75 to 0.68)0.81 (0.27 to 1.36)
Change at CycleC2/Day1 (n= 51, 51, 41)0.27 (-0.21 to 0.75)-0.24 (-0.76 to 0.29)0.30 (-0.25 to 0.84)
Change at CycleC2/Day8 (n= 39, 38, 34)2.00 (1.07 to 2.93)0.03 (-0.61 to 0.66)0.52 (0.05 to 0.99)
Change at CycleC3/Day1 (n= 45, 47, 39)0.64 (0.07 to 1.21)-0.21 (-0.81 to 0.40)0.03 (-0.41 to 0.46)
Change at CycleC3/Day8 (n= 38, 35, 32)1.54 (0.57 to 2.50)0.28 (-0.46 to 1.03)0.41 (-0.00 to 0.82)
Change at CycleC4/Day1 (n= 43, 43, 38)0.72 (-0.18 to 1.62)0.11 (-0.50 to 0.73)0.28 (-0.16 to 0.71)
Change at CycleC4/Day8 (n= 33, 33, 27)1.39 (0.20 to 2.58)1.08 (0.23 to 1.92)1.20 (0.48 to 1.93)
Change at CycleC5/Day1 (n= 35, 34, 29)0.14 (-0.67 to 0.95)-0.05 (-0.88 to 0.78)0.49 (-0.10 to 1.09)
Change at CycleC5/Day8 (n= 29, 26, 25)0.78 (-0.42 to 1.97)0.88 (-0.19 to 1.94)0.76 (-0.03 to 1.55)
Change at CycleC6/Day1 (n= 27, 28, 28)0.18 (-0.76 to 1.12)0.17 (-0.68 to 1.01)0.66 (-0.04 to 1.36)
Change at CycleC6/Day8 (n= 25, 25, 21)1.00 (-0.16 to 2.16)1.04 (0.17 to 1.91)1.20 (0.32 to 2.08)
Change at CycleA1/Day1 (n= 35, 33, 21)0.49 (-0.20 to 1.18)0.39 (-0.34 to 1.13)0.96 (0.28 to 1.64)
Change at CycleA2/Day1 (n= 32, 30, 14)0.25 (-0.52 to 1.02)0.16 (-0.67 to 0.98)0.10 (-0.82 to 1.01)
Change at CycleA3/Day1 (n= 27, 26, 10)0.02 (-0.82 to 0.87)-0.20 (-1.15 to 0.76)0.27 (-0.43 to 0.96)
Change at CycleA4/Day1 (n= 22, 25, 0)0.33 (-0.43 to 1.10)0.23 (-0.58 to 1.05)NA (NA to NA)
Change at CycleA5/Day1 (n= 17, 23, 12)0.36 (-0.54 to 1.27)0.12 (-1.02 to 1.27)0.40 (-0.56 to 1.37)
Change at CycleA6/Day1 (n= 17, 16, 10)0.16 (-0.47 to 0.79)0.28 (-0.82 to 1.39)0.12 (-0.92 to 1.15)
Change at CycleA7/Day1 (n= 15, 15, 0)0.12 (-0.68 to 0.92)0.00 (-1.14 to 1.15)NA (NA to NA)
Change at CycleA8/Day1 (n= 15, 14, 10)-0.07 (-0.96 to 0.82)0.30 (-0.70 to 1.29)0.42 (-0.39 to 1.23)
Change at CycleA9/Day1 (n= 13, 11, 0)-0.13 (-1.03 to 0.77)1.05 (0.09 to 2.00)NA (NA to NA)
Change at CycleA10/Day1 (n= 0, 10, 0)NA (NA to NA)1.03 (0.06 to 2.01)NA (NA to NA)
Change at EOT (n= 40, 35, 31)0.69 (-0.26 to 1.64)0.69 (-0.22 to 1.59)0.91 (0.06 to 1.77)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axitinib + Pemetrexed/Cisplatin (Phase 1)—1/10 (10%)10/10 (100%)
Axitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2)—19/55 (34.5%)54/55 (98.2%)
Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2)—20/58 (34.5%)56/58 (96.6%)
Pemetrexed/Cisplatin (Phase 2)—13/55 (23.6%)54/55 (98.2%)
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventAxitinib + Pemetrexed/Cisplatin (Phase 1)Axitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2)Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2)Pemetrexed/Cisplatin (Phase 2)
Respiratory tract infectionInfections and infestations1/100/550/580/55
VomitingGastrointestinal disorders0/105/552/582/55
NauseaGastrointestinal disorders0/104/551/581/55
DehydrationMetabolism and nutrition disorders0/103/553/580/55
Chest painGeneral disorders0/100/551/582/55
PneumoniaInfections and infestations0/102/550/580/55
PresyncopeNervous system disorders0/102/550/580/55
HypertensionVascular disorders0/102/550/580/55
AnaemiaBlood and lymphatic system disorders0/100/552/581/55
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/100/552/580/55
Most frequent other events
Showing 10 of 127
Most frequent other events
EventAxitinib + Pemetrexed/Cisplatin (Phase 1)Axitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2)Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2)Pemetrexed/Cisplatin (Phase 2)
FatigueGeneral disorders8/1027/5525/5825/55
Decreased appetiteMetabolism and nutrition disorders7/1029/5528/5823/55
HypertensionVascular disorders7/1037/5528/586/55
NauseaGastrointestinal disorders6/1037/5530/5832/55
AnaemiaBlood and lymphatic system disorders5/107/5519/5823/55
NeutropeniaBlood and lymphatic system disorders5/1017/5512/5815/55
DiarrhoeaGastrointestinal disorders5/1022/5520/589/55
AstheniaGeneral disorders5/109/5511/587/55
VomitingGastrointestinal disorders4/1026/5519/5814/55
ConstipationGastrointestinal disorders4/1020/5515/5823/55

Baseline characteristics

Age, Customized
Age, Customized(participants)Axitinib + Pemetrexed/Cisplatin (Phase 1)Axitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2)Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2)Pemetrexed/Cisplatin (Phase 2)Total
Less Than 65 Years5353443117
Greater Than or Equal to 65 Years520241463
Sex: Female, Male
Sex: Female, Male(Participants)Axitinib + Pemetrexed/Cisplatin (Phase 1)Axitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2)Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2)Pemetrexed/Cisplatin (Phase 2)Total
Female121212063
Male9343737117
08

Study locations

52 sites
  • Pfizer Investigational Site
    Huntsville, Alabama 35805, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30341, United States
  • Pfizer Investigational Site
    Decatur, Georgia 30033, United States
  • Pfizer Investigational Site
    Macon, Georgia 31217, United States
  • Pfizer Investigational Site
    Marietta, Georgia 30060, United States
  • Pfizer Investigational Site
    Sandy Springs, Georgia 30342, United States
  • Pfizer Investigational Site
    Bloomington, Illinois 61701, United States
  • Pfizer Investigational Site
    Peoria, Illinois 61615, United States
  • Pfizer Investigational Site
    Hershey, Pennsylvania 17033-0850, United States
  • Pfizer Investigational Site
    West Reading, Pennsylvania 19611, United States
  • Pfizer Investigational Site
    East Providence, Rhode Island 02914, United States
  • Pfizer Investigational Site
    East Providence, Rhode Island 02915, United States
  • Pfizer Investigational Site
    Genova, 16132, Italy
  • Pfizer Investigational Site
    Lido di Camaiore (LU), 55043, Italy
  • Pfizer Investigational Site
    Orbassano (TO), 10043, Italy
  • Pfizer Investigational Site
    Sunto-gun, Shizuoka, Japan
  • Pfizer Investigational Site
    Lubin, 59-300, Poland
  • Pfizer Investigational Site
    Otwock, 05-400, Poland
  • Pfizer Investigational Site
    Pila, 64-920, Poland
  • Pfizer Investigational Site
    Poznan, 60-569, Poland
  • Pfizer Investigational Site
    Poznan, 61-485, Poland
  • Pfizer Investigational Site
    Prabuty, 82-550, Poland
  • Pfizer Investigational Site
    Warszawa, 00-909, Poland
  • Pfizer Investigational Site
    Bacau, 600114, Romania
  • Pfizer Investigational Site
    Iasi, 700106, Romania
  • Pfizer Investigational Site
    Moscow, 115478, Russian Federation
  • Pfizer Investigational Site
    Pyatigorsk, 357502, Russian Federation
  • Pfizer Investigational Site
    Saint-Petersburg, 197089, Russian Federation
  • Pfizer Investigational Site
    St.Petersburg, 194044, Russian Federation
  • Pfizer Investigational Site
    Terrassa, Barcelona 08221, Spain
  • Pfizer Investigational Site
    Castellon, 12002, Spain
  • Pfizer Investigational Site
    Madrid, 28007, Spain
  • Pfizer Investigational Site
    Madrid, 28041, Spain
  • Pfizer Investigational Site
    Palma de Mallorca, 07010, Spain
  • Pfizer Investigational Site
    Sevilla, 41009, Spain
  • Pfizer Investigational Site
    Basel, CH-4016, Switzerland
  • Pfizer Investigational Site
    Basel, CH-4031, Switzerland
  • Pfizer Investigational Site
    Bruderholz, CH-4101, Switzerland
  • Pfizer Investigational Site
    Liestal, CH-4410, Switzerland
  • Pfizer Investigational Site
    Taichung, 402, Taiwan
  • Pfizer Investigational Site
    Taichung, 40705, Taiwan
  • Pfizer Investigational Site
    Taipei, 100, Taiwan
  • Pfizer Investigational Site
    Taipei, 112, Taiwan
  • Pfizer Investigational Site
    Dnipropetrovsk, 49102, Ukraine
  • Pfizer Investigational Site
    Kyiv, 03115, Ukraine
  • Pfizer Investigational Site
    Romford, Essex RM7 0AG, United Kingdom
  • Pfizer Investigational Site
    Northwood, Middlesex HA6 2RN, United Kingdom
  • Pfizer Investigational Site
    Bournemouth, BH7 7DW, United Kingdom
  • Pfizer Investigational Site
    Brighton, BN2 5BE, United Kingdom
  • Pfizer Investigational Site
    Dundee, DD1 9SY, United Kingdom
  • Pfizer Investigational Site
    Middlesex, HA6 2RN, United Kingdom
  • Pfizer Investigational Site
    Poole, BH15 2JB, United Kingdom
09

References and documents

Publications

  • Belani CP, Yamamoto N, Bondarenko IM, Poltoratskiy A, Novello S, Tang J, Bycott P, Niethammer AG, Ingrosso A, Kim S, Scagliotti GV. Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. BMC Cancer. 2014 Apr 25;14:290. doi: 10.1186/1471-2407-14-290. PubMed 24766732 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Mar 2011 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2008
First posted
Oct 8, 2008
Start
Jan 2009
Primary completionActual
Mar 2011
CompletionActual
Mar 2012
Results first posted
Mar 30, 2012
Last update
Oct 28, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00768755
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 8, 2008
Start date
Jan 2009
Primary completion
Mar 2011
Completion
Mar 2012
Results posted
Mar 30, 2012
Last update
Oct 28, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion